A carcinoma that arises from the hepatocytes or intrahepatic bile ducts. The main subtypes are hepatocellular carcinoma (hepatoma) and cholangiocarcinoma.
Comprehensive, easy-to-understand information about this condition
How we create this content →Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
The documentation surrounding carcinoma of the liver and intrahepatic biliary tract is limited due to the complexity and rarity of the condition. With fewer systematic studies conducted, especially in specific genetic contexts, our understanding remains incomplete. This condition affects a relatively small population, making extensive clinical characterization challenging. Ongoing research aims to fill these gaps and improve patient outcomes.
To navigate your care effectively, seek a specialist in hepatology or an oncologist with expertise in liver cancers. Engaging with a genetic counselor may also be beneficial, especially considering the known genetic factors associated with this condition. While no specific patient organizations are identified, resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information and support. Additionally, consider participating in clinical trials to contribute to research and potentially access new treatments.
There are currently several orphan drugs under development for carcinoma of the liver and intrahepatic biliary tract, including 3-bromopyruvate and monoclonal antibodies targeting CD36. Additionally, there are 13 active clinical trials exploring various treatment options. For more information on these trials, you can visit ClinicalTrials.gov at https://clinicaltrials.gov/search?cond=carcinoma%20of%20liver%20and%20intrahepatic%20biliary%20tract. This ongoing research represents hope for new therapeutic strategies.
Actionable guidance for navigating care for carcinoma of liver and intrahepatic biliary tract
To navigate your care effectively, seek a specialist in hepatology or an oncologist with expertise in liver cancers. Engaging with a genetic counselor may also be beneficial, especially considering the known genetic factors associated with this condition. While no specific patient organizations are identified, resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information and support. Additionally, consider participating in clinical trials to contribute to research and potentially access new treatments.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Consider asking your healthcare providers these condition-specific questions
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
No approved therapies yet
Research is ongoing — 2 companies have orphan drug designations for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.